A Newspaper for the health conscious

BD brings tech for accurate, early cervical cancer detection

1 1 1 1 1 1 1 1 1 1 Rating 5.00 (1 Vote)

NEW DELHI: BD Life Sciences-Diagnostic Systems, a leading global medical technology company, on March 12, 2018, announced the launch of a new technology called BD SurePath Direct to Slide.

This is a Liquid Based Cytology (LBC) test intended to be used for screening and detection of cervical cancer, pre-cancerous lesions, atypical cells and all other cytologic categories, said a company statement.

Utilizing BD’s proprietary cell enrichment technique, the technology improved slide quality, whilst accommodating the requirements of labs with lower volume testing.

The new technology is a unique LBC technique that will offer availability of residual sample for conducting important additional follow up tests without the need for repeat sampling.

Dr. Minaxi Desai- Ex Director, Manchester Cytology Centre, UK said, “Women undergoing screening should opt for LBC as a screening test since it has demonstrated ability to detect abnormal cells at the initial stages of pre-cancer, thus preventing cervical cancer from progressing and ensuring cure.”

She said, “LBC also offers the advantage of higher accuracy, shorter screening time and subsequent molecular studies on the same sample.”

Pavan Mocherla, Managing Director, BD–India said, “BD’s cancer diagnostic capabilities focus on improving health outcomes for patients by providing laboratories with solutions that improve quality, enhance laboratory system productivity and inform medical decisions.”

He said, “In India where women’s health is a priority, we are glad that new technology will be able to enhance the standard of patient care, representing the next milestone in cervical cancer screening.”

Leave your comments



  • No comments found


  • No comments found
GLS Pharma


Cubit Pharma

Medical Devices ASEAN 2018